Gwen A Melincoff - Net Worth and Insider Trading
Gwen A Melincoff Net Worth
The estimated net worth of Gwen A Melincoff is at least $28,061 dollars as of 2024-06-02. Gwen A Melincoff is the Director of Soleno Therapeutics Inc and owns about 667 shares of Soleno Therapeutics Inc (SLNO) stock worth over $28,061. Details can be seen in Gwen A Melincoff's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Gwen A Melincoff has not made any transactions after 2019-11-19 and currently still holds the listed stock(s).
Transaction Summary of Gwen A Melincoff
Gwen A Melincoff Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Gwen A Melincoff owns 5 companies in total, including Collegium Pharmaceutical Inc (COLL) , Soleno Therapeutics Inc (SLNO) , and Protalix BioTherapeutics Inc (PLX) among others .
Click here to see the complete history of Gwen A Melincoff’s form 4 insider trades.
Insider Ownership Summary of Gwen A Melincoff
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
COLL | Collegium Pharmaceutical Inc | 2022-05-19 | director |
SLNO | Soleno Therapeutics Inc | 2019-11-19 | director |
PLX | Protalix BioTherapeutics Inc | 2020-01-01 | director |
2016-11-01 | director | ||
2021-03-17 | director |
Gwen A Melincoff Latest Holdings Summary
Gwen A Melincoff currently owns a total of 1 stock. Gwen A Melincoff owns 667 shares of Soleno Therapeutics Inc (SLNO) as of November 19, 2019, with a value of $28,061.
Latest Holdings of Gwen A Melincoff
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
SLNO | Soleno Therapeutics Inc | 2019-11-19 | 667 | 42.07 | 28,061 |
Holding Weightings of Gwen A Melincoff
Gwen A Melincoff Form 4 Trading Tracker
According to the SEC Form 4 filings, Gwen A Melincoff has made a total of 1 transactions in Soleno Therapeutics Inc (SLNO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Soleno Therapeutics Inc is the acquisition of 667 shares on November 19, 2019, which cost Gwen A Melincoff around $15,400.
Insider Trading History of Gwen A Melincoff
- 1
Gwen A Melincoff Trading Performance
GuruFocus tracks the stock performance after each of Gwen A Melincoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gwen A Melincoff is 121.71%. GuruFocus also compares Gwen A Melincoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gwen A Melincoff within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Gwen A Melincoff's insider trading performs compared to the benchmark.
Performance of Gwen A Melincoff
Gwen A Melincoff Ownership Network
Ownership Network List of Gwen A Melincoff
Ownership Network Relation of Gwen A Melincoff
Gwen A Melincoff Owned Company Details
What does Collegium Pharmaceutical Inc do?
Who are the key executives at Collegium Pharmaceutical Inc?
Gwen A Melincoff is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP & Chief Financial Officer Tupper Colleen , EVP & Chief Commercial Officer Scott Dreyer , and director & President and CEO Joseph Ciaffoni .
Collegium Pharmaceutical Inc (COLL) Insider Trades Summary
Over the past 18 months, Gwen A Melincoff made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 229,765 shares made by Joseph Ciaffoni , a net sale of 159,410 shares made by Scott Dreyer , and a net sale of 298,612 shares made by Michael Thomas Heffernan .
In summary, during the past 3 months, insiders sold 156,711 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 156,711 shares. During the past 18 months, 801,877 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 801,877 shares.
Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Collegium Pharmaceutical Inc Insider Transactions
Gwen A Melincoff Mailing Address
Above is the net worth, insider trading, and ownership report for Gwen A Melincoff. You might contact Gwen A Melincoff via mailing address: C/o Tobira Therapeutics, Inc., 701 Gateway Boulevard, South San Francisco Ca 94080.